# Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

> **NCT07081360** · PHASE3 · RECRUITING · sponsor: **Minia University** · enrollment: 262 (estimated)

## Conditions studied

- Pancreas Cancer
- Periampullary Cancer
- Periampullary Carcinoma Resectable
- Pancreatic Cancer Resectable
- Ampullary Cancer
- Pancreas Adenocarcinoma

## Interventions

- **DRUG:** Neoadjuvant chemotherapy
- **PROCEDURE:** Upfront Surgery Group

## Key facts

- **NCT ID:** NCT07081360
- **Lead sponsor:** Minia University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2028-07-20
- **Final completion:** 2028-08-20
- **Target enrollment:** 262 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07081360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07081360, "Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07081360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*